• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Plastin 3 protein mutations may be involved in osteoporosis

bys25qthea
October 18, 2013
in Chronic Disease, Genetics
Reading Time: 3 mins read
Repeat bone mineral density testing may not improve prediction of fracture outcomes
Share on FacebookShare on Twitter

Image: PD

1. Pathogenic variants of the plastin 3 (PLS3) gene were identified in five families with X-linked osteoporosis and osteoporotic fractures.  

2. A rare PLS3 variant was found to be associated with decreased BMD and increased risk of fracture among elderly heterozygous women. 

3. Zebrafish with pls3 knockdown developed skeletal malformations that were reversible with administration of human PLS3 mRNA. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Osteoporosis is a multifactorial disease with a complex pathophysiology involving both genetic and environmental factors. In this study, analyses of genomic data from families with X-linked osteoporosis led to the identification of several novel PLS3 gene variants. The study findings suggest that the PLS3 protein is important to bone health and that variants in its gene may have a role in multifactorial osteoporosis. The authors hypothesize that the PLS3 protein is important in the mechanosensitivity of osteocyte dendrites. Thus, mutations in PLS3 would result in decreased mechanosensing, leading to dysregulation of bone modeling or remodeling and ultimately to osteoporosis. The association between the rare PLS3 gene variant and osteoporosis was examined in a population of Dutch men and women. Additional studies with larger cohorts and greater ethnic variability are needed to further assess this relationship in the general population.

RELATED REPORTS

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

Click to read the study in NEJM

Relevant Reading: Recent progress in understanding the genetic susceptibility to osteoporosis

In-Depth [prospective cohort study]: This study analyzed the genomes of families with X-linked osteoporosis and fractures without mutations in collagen type Iα1 or type Iα2 genes. Families 1 to 5 carried pathogenic variants for PLS3 and families 6 to 10 had been referred based on suspicion of osteogenesis imperfect type I. A single deleterious hemizygous frameshift in exon 3 of PLS3 was discovered through X-linked whole-exome sequencing of affected males from Family 1. Subsequent Sanger sequencing of all PLS3 exons in 95 affected male patients revealed four additional pathogenic variants in families 2 through 5 and a rare variant in families 6 through 10.

Genotyping for the rare variant was conducted in the three cohorts of the Rotterdam Study, a Dutch study analyzing the association of genetic factors with bone mineral density (BMD) and fractures. Heterozygous female carriers of the rare variant of PLS3 had significantly increased risk of fracture as compared to noncarriers. Fixed-effect model analysis of two of the cohorts found the odds ratio of fracture to be 1.95 (95% CI, 1.39 to 2.74; P<0.001). Combined analysis of the three Rotterdam Study cohorts showed a small but significantly decreased BMD at the lumbar spine and femoral neck in heterozygous women (P=0.008, and P=0.04, respectively). No significant difference was found in men.

In vivo studies of zebrafish found that PLS3 knockdown led to severe dysplasia of craniofacial skeletal elements. In addition, knockdown zebrafish larvae developed gross morphologic abnormalities that were specific and reversed dose-dependently with injections of human PLS3 mRNA.

By Xu Gao and Adrienne Cheung

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: osteoporosisPLS3
Previous Post

Sham procedures effective in generating placebo effect among migraine patients

Next Post

Frey procedure may yield better outcomes in chronic pancreatitis

RelatedReports

Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

April 17, 2025
#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women
StudyGraphics

#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women

January 22, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Chronic Disease

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

January 13, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Nephrology

Denosumab increases risk of severe hypocalcemia in women with osteoporosis and chronic kidney disease

November 18, 2024
Next Post
Wound surgical device found ineffective at infection control: ROSSINI Trial

Frey procedure may yield better outcomes in chronic pancreatitis

Motion Displacement Test is accurate in screening for glaucoma

One-year of Herceptin preferable to two-year regimen

Age, cardiac comorbidities linked to increased risk of trastuzumab-related CHF

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deficits in executive function are not universal among patients with alcohol use disorder
  • Choice of bicarbonate-buffered solution versus compound sodium lactate as the intraoperative crystalloid solution during abdominal surgery remains unclear
  • Artificial intelligence (AI)-based coronary calcium quantification successfully identified patients who could benefit from lipid-lowering therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.